-
Tytuł:
-
Long-Term Follow-up after Treatment Discontinuation in Patients with Chronic Myeloid Leukemia: The Korean Imatinib Discontinuation (KID) Study
-
Autorzy:
-
Zang, Dae Young
Lee, Won Sik
Mun, Yeung-Chul
Do, Young Rok
Oh, Sukjoong
Lee, Sung-Eun
Choi, Soo Young
Kim, Dong-Wook
-
Źródło:
-
Blood; November 2018, Vol. 132 Issue: 1, Number 1 Supplement 1 p4252-4252, 1p
-
BackgroundWith first-line imatinib (IM) therapy, approximately 50% of CP CML patients achieve undetectable molecular residual disease (UMRD). The recent several discontinuation clinical trials have demonstrated that IM discontinuation can be employed based on clinical study in patients who had enough IM therapy and UMRD durations prior to IM discontinuation. In our previous report, we have reported that of 90 patients with follow-up ≥12 months, the probability of sustained major molecular response (MMR) at 12 months and 24 months was 62.2% and 58.5%, respectively. However, currently, the issue on the occurrence of late relapse with a long-term follow-up after IM discontinuation is important. Therefore, here we analyzed the long-term follow-up results of the KID study.